Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution